ACLARIS THERAPEUTICS INC (ACRS) — insider trading
Health Care · NASDAQ
ACLARIS THERAPEUTICS INC (ACRS) has 37 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 37 (latest 2026-06-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | GOWEN MAXINE | Director | Option exercise / conversion (derivative) | 11,580 | $0.00 | $0 | Form 4 |
| 2026-06-05 | GOWEN MAXINE | Director | Option exercise / conversion | 11,580 | — | — | Form 4 |
| 2026-06-05 | MILANO VINCENT | Director | Option exercise / conversion (derivative) | 11,580 | $0.00 | $0 | Form 4 |
| 2026-06-05 | MILANO VINCENT | Director | Option exercise / conversion | 11,580 | — | — | Form 4 |
| 2026-06-05 | Molineaux Christopher P. | Director | Option exercise / conversion (derivative) | 11,580 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Molineaux Christopher P. | Director | Option exercise / conversion | 11,580 | — | — | Form 4 |
| 2026-06-05 | Humphries William D. | Director | Option exercise / conversion (derivative) | 11,580 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Humphries William D. | Director | Option exercise / conversion | 11,580 | — | — | Form 4 |
| 2026-06-05 | SCHIFF ANDREW N | Director | Option exercise / conversion (derivative) | 11,580 | $0.00 | $0 | Form 4 |
| 2026-06-05 | SCHIFF ANDREW N | Director | Option exercise / conversion | 11,580 | — | — | Form 4 |
| 2026-06-05 | Mehra Anand | Director | Option exercise / conversion (derivative) | 11,580 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Mehra Anand | Director | Option exercise / conversion | 11,580 | — | — | Form 4 |
| 2026-06-04 | GOWEN MAXINE | Director | Grant / award / vesting (derivative) | 10,987 | $0.00 | $0 | Form 4 |
| 2026-06-04 | GOWEN MAXINE | Director | Grant / award / vesting (derivative) | 42,350 | $0.00 | $0 | Form 4 |
| 2026-06-04 | MILANO VINCENT | Director | Grant / award / vesting (derivative) | 10,987 | $0.00 | $0 | Form 4 |
| 2026-06-04 | MILANO VINCENT | Director | Grant / award / vesting (derivative) | 42,350 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Molineaux Christopher P. | Director | Grant / award / vesting (derivative) | 10,987 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Molineaux Christopher P. | Director | Grant / award / vesting (derivative) | 42,350 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Humphries William D. | Director | Grant / award / vesting (derivative) | 10,987 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Humphries William D. | Director | Grant / award / vesting (derivative) | 42,350 | $0.00 | $0 | Form 4 |
| 2026-06-04 | SCHIFF ANDREW N | Director | Grant / award / vesting (derivative) | 10,987 | $0.00 | $0 | Form 4 |
| 2026-06-04 | SCHIFF ANDREW N | Director | Grant / award / vesting (derivative) | 42,350 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Mehra Anand | Director | Grant / award / vesting (derivative) | 10,987 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Mehra Anand | Director | Grant / award / vesting (derivative) | 42,350 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Hall Jesse Wayne | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 36,375 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Hall Jesse Wayne | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 9,330 | $4.41 | $41.1K | Form 4 |
| 2026-05-01 | Hall Jesse Wayne | Officer (Chief Medical Officer) | Option exercise / conversion | 36,375 | — | — | Form 4 |
| 2026-04-23 | Leonard Braden Michael | 10% owner | Open-market sale | 300,000 | $4.53 | $1.36M | Form 4 |
| 2026-03-01 | Balthaser Kevin | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,375 | $0.00 | $0 | Form 4 |
| 2026-03-01 | Balthaser Kevin | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 677 | $2.87 | $1.9K | Form 4 |
| 2026-03-01 | Balthaser Kevin | Officer (Chief Financial Officer) | Option exercise / conversion | 2,375 | — | — | Form 4 |
| 2026-02-02 | Kolbeck Roland Wilhelm | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 334,900 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Kolbeck Roland Wilhelm | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 95,700 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Davis Hugh M. | Director, Officer (President and COO) | Grant / award / vesting (derivative) | 336,300 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Davis Hugh M. | Director, Officer (President and COO) | Grant / award / vesting (derivative) | 96,100 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Walker Neal | Director, Officer (CEO) | Grant / award / vesting (derivative) | 961,700 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Walker Neal | Director, Officer (CEO) | Grant / award / vesting (derivative) | 274,800 | $0.00 | $0 | Form 4 |
Ask the chat about ACRS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ACLARIS THERAPEUTICS INC (ACRS).
Last updated 2026-06-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.